IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression

Hum Reprod. 2005 Sep;20(9):2441-7. doi: 10.1093/humrep/dei101. Epub 2005 May 26.

Abstract

Background: Down-regulation with GnRH agonist has been suggested to result in a profound suppression of LH bioactivity, reduced estradiol synthesis, and thus impaired IVF and pregnancy outcome. The aims of this study were: (i) to assess the usefulness of serum LH measurement on stimulation day 1 as a predictor of ovarian response, conception and pregnancy outcome in patients treated with long-term down-regulation with GnRH agonist and recombinant FSH, and (ii) to define the best threshold LH value, if any, to discriminate between women with different outcomes of IVF.

Methods: Records of 2625 cycles in 1652 infertile women undergoing IVF (n = 1856) and/or ICSI (n = 769) treatment were reviewed.

Results: The range of LH concentrations on stimulation day 1 overlapped among non-conception cycles, conception cycles, ongoing pregnancies and early pregnancy losses. Receiver operating characteristic (ROC) analysis showed that serum LH concentrations on stimulation day 1 were unable to discriminate between conception and non-conception cycles (AUC(ROC) = 0.51; 95% CI: 0.49-0.54) or ongoing pregnancies versus early pregnancy loss groups (AUC(ROC) = 0.52; 95% CI: 0.47-0.57). Stratification for various low serum levels of LH did not reveal significant differences with respect to conception or pregnancy outcome among different LH levels on stimulation day 1.

Conclusions: Serum LH concentration on stimulation day 1 cannot predict ovarian response, conception and pregnancy outcome in women receiving long-term down-regulation during assisted reproduction treatment.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Female
  • Fertilization in Vitro*
  • Follicle Stimulating Hormone / therapeutic use*
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Infertility, Female / blood*
  • Infertility, Female / drug therapy*
  • Luteinizing Hormone / blood*
  • Ovulation Induction
  • Pituitary Gland / drug effects
  • Polycystic Ovary Syndrome / blood
  • Polycystic Ovary Syndrome / drug therapy
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Outcome*
  • Recombinant Proteins / therapeutic use
  • Retrospective Studies
  • Sperm Injections, Intracytoplasmic

Substances

  • Biomarkers
  • Recombinant Proteins
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone